1,270
Participants
Start Date
May 23, 2017
Primary Completion Date
June 14, 2018
Study Completion Date
June 14, 2018
Use Phase (Ulipristal Acetate, 30 mg)
"All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take 30 mg of ulipristal acetate.~Subjects are to use the investigational product based on their understanding of the directions on the outer packaging including Drug Facts Label and inside the product packaging (in the Consumer Information Leaflet)."
HRA Pharma Investigational Site, New York
HRA Pharma Investigational Site, Raleigh
HRA Pharma Investigational Site, Durham
HRA Pharma Investigational Site, Orlando
HRA Pharma Investigational Site, Pembroke Pines
HRA Pharma Investigational Site, Miami
HRA Pharma Investigational Site, Tampa
HRA Pharma Investigational Site, St. Petersburg
HRA Pharma Investigational Site, Fort Myers
HRA Pharma Investigational Site, Andover
HRA Pharma Investigational Site, Saint Louis Park
HRA Pharma Investigational Site, Belleville
HRA Pharma Investigational Site, Manchester
HRA Pharma Investigational Site, St Louis
HRA Pharma Investigational Site, St Louis
HRA Pharma Investigational Site, City of Saint Peters
HRA Pharma Investigational Site, Kansas City
HRA Pharma Investigational Site, Denver
HRA Pharma Investigational Site, Denver
HRA Pharma Investigational Site, Boulder
HRA Pharma Investigational Site, Albuquerque
HRA Pharma Investigational Site, Albuquerque
HRA Pharma Investigational Site, Las Vegas
HRA Pharma Investigational Site, Rancho Cucamonga
HRA Pharma Investigational Site, Portland
HRA Pharma Investigational Site, Seattle
HRA Pharma Investigational Site, Seattle
HRA Pharma Investigational Site, Bremerton
HRA Pharma Investigational Site, Puyallup
HRA Pharma Investigational Site, Tacoma
HRA Pharma Investigational Site, Hackensack
HRA Pharma Investigational Site, Morristown
HRA Pharma Investigational Site, New Brunswick
HRA Pharma Investigational Site, Trenton
Lead Sponsor
HRA Pharma
INDUSTRY